Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 5/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3658862 | 0.94 | CYP2A6 (0.63) | CYP2A6ALDH1A1MAPTHPGDMAOB | |
| SCHEMBL834744 | 0.87 | CYP2A6 (0.68) | CYP2A6ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL21215857 | 0.82 | CYP2A6 (0.69) | CYP2A6ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL15105728 | 0.82 | CYP2A6 (0.69) | CYP2A6ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL1285483 | 0.81 | KDM4E (0.55) | CYP2A6ALDH1A1MAPTHPGDCYP1A2 | |
| SCHEMBL29766531 | 0.81 | KDM4E (0.55) | CYP2A6ALDH1A1MAPTHPGDCYP1A2 | |
| SCHEMBL599006 | 0.80 | CYP2A6 (0.79) | CYP2A6ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL29451111 | 0.80 | CYP2A6 (0.79) | CYP2A6ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL12520344 | 0.79 | CYP1A2 (0.46) | CYP2A6ALDH1A1HPGDCYP1A2CES2 | |
| SCHEMBL14060956 | 0.79 | LCK (0.62) | CYP2A6ALDH1A1MAOBCYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9500653-B2 | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same | YALE UNIVERSITY (US) | 2016-11-22 | — | — | US | disclosed |
| EP-2285787-B1 | 3-SUBSTITUTED PROPANAMINE COMPOUNDS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2015-08-26 | — | — | EP | disclosed |
| US-20140302523-A1 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same | YALE UNIVERSITY (US) | 2014-10-09 | — | — | US | disclosed |
| US-8404730-B2 | 3-substituted propanamine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-03-26 | — | — | US | disclosed |
| US-20120046312-A1 | 3-SUBSTITUTED PROPANAMINE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-02-23 | — | — | US | disclosed |
| US-8101642-B2 | 3-substituted propanamine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-01-24 | — | — | US | disclosed |
| EP-2285787-A2 | 3-SUBSTITUTED PROPANAMINE COMPOUNDS | SK Holdings Co., Ltd. (KR) | 2011-02-23 | — | — | EP | disclosed |
| US-20100311789-A1 | 3-Substituted Propanamine Compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2010-12-09 | — | — | US | disclosed |
| WO-2009148290-A2 | 3-SUBSTITUTED PROPANAMINE COMPOUNDS | SK HOLDINGS CO., LTD. (KR) | 2009-12-10 | — | — | WO | disclosed |
| CN-86101420-A | The acidylate of naphthalene | — | 1986-11-12 | — | — | CN | disclosed |
| EP-0196805-A1 | Acylation of naphthalenes | CELANESE CORPORATION (US) | 1986-10-08 | — | — | EP | disclosed |
| US-4593125-A | In anhydrous hydrogen fluoride | CELANESE CORPORATION (US) | 1986-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046312-A1 | 3-SUBSTITUTED PROPANAMINE COMPOUNDS | ADRB3, PNMT, OPRK1 | CYP2A6 1434/4885ALDH1A1 177/4885MAPT 544/4885 |
| US-20100311789-A1 | 3-Substituted Propanamine Compounds | ADRB3, PNMT, OPRK1 | CYP2A6 1434/4885ALDH1A1 177/4885MAPT 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.